Funding, News and Announcements

Reminder: Letter of Intent Deadline is Tuesday, September 1st at 2:00pm EDT.

The Weston Brain Institute has launched the Early Phase Clinical Trials 2015 program to help outstanding Canadian researchers accelerate the development of treatments for neurodegenerative diseases of aging. The deadline to submit a Letter of Intent is fast approaching.

Apply to this program through the Institute’s online grant management system here.

Information about the program can be found here.

Goal: To provide funding for Phase I and II clinical trials to accelerate the development of therapeutics for neurodegenerative diseases of aging

Funding: Up to $1,500,000 for up to 4 years

Eligibility: The Principal applicant must be a researcher(s) with a full-time staff or faculty appointment (at or above the level of Assistant Professor or equivalent) at institutions that are registered CRA qualified donees in Canada. Projects must focus on the development of therapeutics for the symptomatic relief, disease modification, or prevention of neurodegenerative diseases of aging as we define them (AD, PD, ALS, DLB, FTD, PSP, MSA, and MCI as prodromal to one of these diseases).

All approaches below qualify for this funding opportunity:

Pharmacological approaches (small molecules, biologics, cell therapies, vaccines, including drug repositioning and repurposing)

Medical Devices
Surgical Interventions
Magnetic or electrical brain stimulation
** Complementary approaches (e.g. exercise, acupuncture, foods, or dietary or nutritional supplements) do not qualify.

The Institute welcomes inquiries about our funding programs at neuro@weston.ca or 416-935-4056.